Optimizing care for psoriatic patients requiring systemic therapies : how will COVID-19 disease transform risk perceptions?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:313 |
|---|---|
| Enthalten in: |
Archives of dermatological research - 313(2021), 2 vom: 09. März, Seite 127-128 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Talamonti, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4Z8R6ORS6L |
|---|
| Anmerkungen: |
Date Completed 16.02.2021 Date Revised 18.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00403-020-02103-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312247672 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312247672 | ||
| 003 | DE-627 | ||
| 005 | 20231225144013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00403-020-02103-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1040.xml |
| 035 | |a (DE-627)NLM312247672 | ||
| 035 | |a (NLM)32647977 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Talamonti, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimizing care for psoriatic patients requiring systemic therapies |b how will COVID-19 disease transform risk perceptions? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2021 | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a apremilast |2 NLM | |
| 650 | 7 | |a UP7QBP99PN |2 NLM | |
| 700 | 1 | |a Tofani, L |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, L |e verfasserin |4 aut | |
| 700 | 1 | |a Galluzzo, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of dermatological research |d 1986 |g 313(2021), 2 vom: 09. März, Seite 127-128 |w (DE-627)NLM00029716X |x 1432-069X |7 nnns |
| 773 | 1 | 8 | |g volume:313 |g year:2021 |g number:2 |g day:09 |g month:03 |g pages:127-128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00403-020-02103-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 313 |j 2021 |e 2 |b 09 |c 03 |h 127-128 | ||